Company news

Pelthos Therapeutics Inc. news in 2026

Pelthos Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026

November 4, 2026

Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin

October 30, 2026

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

August 13, 2026

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

May 14, 2026

Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026

May 1, 2026

Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

April 14, 2026

Pelthos Therapeutics Announces CFO Transition

April 10, 2026

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

March 31, 2026

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

March 19, 2026

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

March 12, 2026

Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

March 9, 2026

Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

January 13, 2026

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

January 5, 2026

Calls in 2026

Decks in 2026